Recent Developments in Glioblastoma-On-A-Chip for Advanced Drug Screening Applications.

Area of Science:

• Biomedical Engineering
• Cancer Research
• Neuro-oncology

Background:

• Glioblastoma (GBM) is a highly aggressive brain cancer with limited treatment options.
• The blood-brain barrier (BBB) impedes drug delivery, complicating GBM therapy.
• Traditional 2D cell culture models fail to capture the complexity of the GBM tumor microenvironment.

Purpose of the Study:

• To review the current landscape of Glioblastoma-on-a-chip (GBM-on-a-chip) models.
• To highlight the applications of these models in drug screening for GBM.
• To discuss existing challenges and future prospects for GBM-on-a-chip technology.

Main Methods:

• Review of existing literature on organ-on-a-chip (OoC) technologies applied to GBM.
• Analysis of studies utilizing GBM-on-a-chip platforms for disease modeling and drug evaluation.
• Discussion of the advantages of OoC models over conventional 2D and 3D cell cultures.

Main Results:

• GBM-on-a-chip models effectively recapitulate aspects of human GBM physiology and the tumor microenvironment.
• These models show significant potential for high-throughput drug screening and personalized medicine approaches.
• A growing body of research indicates the utility of GBM-on-a-chip systems in advancing GBM research.

Conclusions:

• GBM-on-a-chip models represent a significant advancement over traditional in vitro methods for studying glioblastoma.
• These platforms hold promise for accelerating the development of effective GBM therapeutics and reducing reliance on animal models.
• Further development and standardization of GBM-on-a-chip models are crucial for clinical translation.